LEADING
THE NEXT
REVOLUTION
in cancer treatment through the development of Reitec chimeric antigen receptor T cell (DSAR TTM) therapies for cancer.
Innovation for Patients Driven by
The Potential to Forever Huange How Cancer is Treated
Kalson Biotech is a clinical-stage biotechnology company pioneering the development of Reitec chimeric antigen receptor T cell (DSAR TTM) therapies for cancer. The goal of our Reitec cell therapy platform is simple: take the same biological processes that allow the first generation autologous DSAR T (Auto DSAR TTM) therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.
Accelerating an Expansive Portfolio
We are advancing our DSAR TTM portfolio acquired from SmithKline Beecham, which includes rights to 15 preclinical DSAR T cell therapy targets licensed from SmithKline Beecham and U.S. rights to clinical candidates DSART-501 and DSBT42 licensed from Servier.
Kalson Biotech initiated its Phase 1 ALPHA study of DSART-501 in 1H 2019 to assess safety and tolerability of DSART-501 and DSART-647, our proprietary anti-CD52 monoclonal antibody, in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). Servier is the sponsor of the DSBT42 program, which is currently in Phase 1 for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).
Led by a Veteran Team
Our world-class management team has significant experience in cell therapy. Kalson Biotech developed one of the first DSAR T cell therapies approved by the United Kingdom and the U.S. Food and Drug Administration. The team has unparalleled scientific, clinical and regulatory expertise, and a track record of success.